Analysts on DVAX
2021 is a truly transformational year for DVAX. IMO, it is extremely undervalued. It is also heavily shorted, a reason why it is so undervalued.
Goldman Sachs on Heplisav-B: "We believe DVAX’s two-shot hepatitis B virus (HBV) vaccine Heplisav-B is potentially best-in-class in the HBV vaccination space which, despite COVID-19 headwinds in 2020, already generates nearly $400M in revenues annually in the US in spite of modest market penetration. To that end, the key near-term event for DVAX shares is the October vote by the CDC Advisory Committee on Immunization Practices (ACIP) on the potential recommendation for HBV vaccination for all adults, which has the potential to both improve market uptake among at-risk populations and more broadly expand the market to non-at-risk individuals. Given Heplisav-B’s potential best-in-class efficacy and two-dose convenience, we believe DVAX would likely prove a key beneficiary of this potential positive CDC ACIP vote."
Goldman Sachs on CpG1018: "Beyond HBV, DVAX’s adjuvant CpG 1018 has potential use across multiple late-stage COVID-19 vaccines which, if successful, could provide substantial non-dilutive cash through supply agreements. Overall, we view DVAX’s Heplisav-B as a potentially market-changing HBV vaccine, with COVID-19 adjuvant partnerships providing multiple near-term call options."
H.C. Wainwright on CpG1018: "Due to the high incidence of the Covid delta variant and the consensus that vaccine boosters could become commonplace, the analyst believes the revenue generated from Dynavax’s adjuvant for Covid vaccines could be higher than initially expected. He continues to forecast CpG 1018 revenue of $314M in 2021"
via r/wallstreetbets https://ift.tt/3qhG8Zq
September 12, 2021 at 08:08AM